NOVARTIS AG
corporate_fare Company Profile
NOVARTIS AG (NYSE:NVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for NVS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for NVS spans 6-K, 424B5, FWP, 20-F.
Recent high-impact activity:
- Activist Investor Demands Board Shakeup at Novartis After $12B Drug Flop
- Novartis's Phase III DM1 drug fails primary endpoint; maintains guidance despite setback
- Pelacarsen Stumbles in Phase III Cardiovascular Outcomes Trial
- Remibrutinib clears Phase III in RMS, setting up global filings for Novartis
- Novartis Q2: Sales Return to Growth, Pipeline Advances, and Guidance Reaffirmed
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for NVS, detected from its recent SEC filings · based on capital-structure filings through 2026-03-17.
Debt Offering Finalized · Multi-Tranche Structure
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
NVS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.